AEGEAN Trial: New Data on Neoadjuvant Chemotherapy/Immunotherapy + Adjuvant Immunotherapy Released

AEGEAN Trial: New Data on Neoadjuvant Chemotherapy/Immunotherapy + Adjuvant Immunotherapy Released

2024.01.18
According to the preliminary results of the phase III AEGEAN trial (NCT03800134) interim analysis presented at the AACR Annual Meeting in 2023, in patients with resectable non-small cell lung cancer (NSCLC), the perioperative durvalumab combined with platinum-based neoadjuvant chemotherapy showed statistically significant improvements in pathological complete response (pCR) and event-free survival (EFS) compared to placebo combined with chemotherapy.
ESMO Hot Topic | Professor Han Liang : Phase III MATTERHORN Study on the Verge of Success, Significant Improvement in pCR with Neoadjuvant Durvalumab for Gastric Cancer

ESMO Hot Topic | Professor Han Liang : Phase III MATTERHORN Study on the Verge of Success, Significant Improvement in pCR with Neoadjuvant Durvalumab for Gastric Cancer

2023.11.17
The 2023 ESMO Annual Meeting took place from October 20th to 24th in Madrid, Spain. As a highly authoritative annual event in the field of oncology, it unveils cutting-edge advancements in cancer research each year. In the gastric cancer domain this year, the global Phase III MATTERHORN study on the anti-PD-L1 monoclonal antibody durvalumab was presented as a Late-breaking Abstract (LBA) with mid-term analysis results (Abstract No: LBA73). The interim analysis revealed a clinically and statistically significant increase in the pathologic complete response (pCR) rate with the neoadjuvant treatment regimen of durvalumab in combination with FLOT. The MATTERHORN study holds promise as the first positive neoadjuvant Phase III immunotherapy regimen for gastric cancer. "Oncology Frontier" is pleased to invite Professor Han Liang from Tianjin Medical University Cancer Institute to provide an in-depth interpretation of this study.
AEGEAN Trial: New Data on Neoadjuvant Chemotherapy/Immunotherapy + Adjuvant Immunotherapy Released

AEGEAN Trial: New Data on Neoadjuvant Chemotherapy/Immunotherapy + Adjuvant Immunotherapy Released

2023.10.12
According to the preliminary results of the phase III AEGEAN trial (NCT03800134) interim analysis presented at the AACR Annual Meeting in 2023, in patients with resectable non-small cell lung cancer (NSCLC), the perioperative durvalumab combined with platinum-based neoadjuvant chemotherapy showed statistically significant improvements in pathological complete response (pCR) and event-free survival (EFS) compared to placebo combined with chemotherapy. [1,2]